

Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DN

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.

08/808,629 02/28/97 ROY-CHOWDHURY J ENZ-55

RONALD C FEDUS

CORPORATION & PATENT COUNSEL

ENZO BIOCHEM INC

527 MADISON AVENUE 9TH FLOOR

NEW YORK NY 10022

EXAMINER

SCHWADRON, R

ART UNIT PAPER NUMBER

1644 4

DATE MAILED:

05/12/99

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The instant application discloses nucleic acid sequences on page 34 for which no sequence listing has been submitted.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication should be directed to Examiner Ron Schwadron, Ph.D., Art Unit 1644, whose telephone number is (703) 308-4680. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800 1 600

Ron Schwadron, Ph.D. May 10, 1999

RECEIVED

AUG 0 3 1999

TECH CENTER 1500/2900

JUL 2 8 1999

Application No.: 08/ NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
X	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
X	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7.	Other:
Applicant Must Provide:		
Ŕ	•	n <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
Ų,	Ai in	n <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry- to the specification.
Ø	ap	statement that the content of the paper and computer readable copies are the same and, where oplicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 325(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



<110> ENZO THERAPEUTICS, INC.

<120> NOVEL PROCESSES IMPLEMENTING SELECTIVE IMMUNE DOWN REGULATION (SIDR)

<130> ENZ-55 SEQUENCE LISTING 072699

<140> 08/808,629

<141> 1997-02-28

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 20

<212> DNA

<213> HUMAN BUGT1 GENE

<400> 1

aaggaaaggg tccgtcagca

<210> 2

<211> 19

<212> DNA

<213> HUMAN BUGT1 GENE

<400> 2

ccagcagctg cagcagagg

20

19

RECEIVED

AUG 0 5 1999

TECH CENTER 1507/7000

Al'